Graham Capital Management L.P. Sells 8,600 Shares of Medtronic PLC $MDT

Posted by Francis Steltz on Jun 17th, 2026

Graham Capital Management L.P. trimmed its position in shares of Medtronic PLC (NYSE:MDT – Free Report) by 18.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 38,642 shares of the medical technology company’s stock after selling 8,600 shares during the quarter. Graham Capital Management L.P.’s holdings in Medtronic were worth $3,712,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Persistent Asset Partners Ltd bought a new stake in Medtronic during the fourth quarter worth about $481,000. Howe & Rusling Inc. grew its stake in Medtronic by 43.7% during the fourth quarter. Howe & Rusling Inc. now owns 94,051 shares of the medical technology company’s stock worth $9,035,000 after buying an additional 28,624 shares during the last quarter. Opal Capital LLC bought a new stake in Medtronic during the fourth quarter worth about $319,000. Rothschild Wealth LLC acquired a new position in shares of Medtronic during the fourth quarter worth approximately $566,000. Finally, L2 Asset Management LLC lifted its position in shares of Medtronic by 7.2% during the fourth quarter. L2 Asset Management LLC now owns 6,519 shares of the medical technology company’s stock worth $626,000 after purchasing an additional 439 shares in the last quarter. 82.06% of the stock is owned by institutional investors.

Medtronic Price Performance

MDT opened at $81.36 on Wednesday. Medtronic PLC has a one year low of $73.31 and a one year high of $106.33. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. The company’s 50 day simple moving average is $80.62 and its 200-day simple moving average is $90.95. The stock has a market capitalization of $104.45 billion, a P/E ratio of 21.81, a price-to-earnings-growth ratio of 2.16 and a beta of 0.58.

Medtronic (NYSE:MDT – Get Free Report) last announced its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a net margin of 13.20% and a return on equity of 14.61%. The firm had revenue of $9.81 billion for the quarter, compared to analysts’ expectations of $9.62 billion. During the same period last year, the firm earned $1.62 earnings per share. The business’s revenue for the quarter was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Sell-side analysts anticipate that Medtronic PLC will post 5.94 earnings per share for the current fiscal year.

Medtronic Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 17th. Shareholders of record on Friday, June 26th will be paid a $0.72 dividend. The ex-dividend date of this dividend is Friday, June 26th. This is a boost from Medtronic’s previous quarterly dividend of $0.71. This represents a $2.88 dividend on an annualized basis and a yield of 3.5%. Medtronic’s payout ratio is 76.14%.

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the firm’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $80.44, for a total value of $336,963.16. Following the transaction, the executive vice president directly owned 37,227 shares of the company’s stock, valued at approximately $2,994,539.88. This trade represents a 10.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.26% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on MDT shares. TD Cowen reissued a “buy” rating and set a $119.00 price target on shares of Medtronic in a research note on Thursday, June 4th. Wall Street Zen cut shares of Medtronic from a “buy” rating to a “hold” rating in a research note on Saturday, April 11th. Evercore set a $106.00 price target on shares of Medtronic and gave the company an “outperform” rating in a research note on Thursday, April 9th. Weiss Ratings cut shares of Medtronic from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, May 21st. Finally, Barclays increased their price target on shares of Medtronic from $118.00 to $120.00 and gave the company an “overweight” rating in a research note on Wednesday, April 1st. Seventeen analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $99.00.

Read Our Latest Stock Analysis on MDT

Medtronic Profile

(Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).